Patrick J. McEnany net worth and biography

Patrick McEnany Biography and Net Worth

Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for the Jackson Memorial Hospital Foundation.

What is Patrick J. McEnany's net worth?: The estimated net worth of Patrick J. McEnany is at least $85.58 million as of May 15th, 2023. Mr. McEnany owns 3,945,436 shares of Catalyst Pharmaceuticals stock worth more than $85,576,507 as of November 15th. This net worth evaluation does not reflect any other investments that Mr. McEnany may own. Learn More about Patrick J. McEnany's net worth.
How do I contact Patrick J. McEnany?: The corporate mailing address for Mr. McEnany and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Patrick J. McEnany's contact information.
Has Patrick J. McEnany been buying or selling shares of Catalyst Pharmaceuticals?: Patrick J. McEnany has not been actively trading shares of Catalyst Pharmaceuticals in the last ninety days. Most recently, Patrick J. Mcenany sold 26,151 shares of the business's stock in a transaction on Monday, May 15th. The shares were sold at an average price of $13.23, for a transaction totalling $345,977.73. Following the completion of the sale, the chief executive officer now directly owns 3,945,436 shares of the company's stock, valued at $52,198,118.28. Learn More on Patrick J. McEnany's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 8/21/2024.

Patrick J. McEnany Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2023	Sell	26,151	$13.23	$345,977.73	3,945,436
11/21/2022	Sell	150,000	$15.33	$2,299,500.00	3,902,606
11/18/2022	Sell	350,000	$15.62	$5,467,000.00	3,902,606
9/13/2022	Sell	80,765	$15.33	$1,238,127.45	4,849,452
8/23/2021	Sell	82,617	$5.62	$464,307.54	4,928,304
8/20/2021	Sell	54,161	$5.52	$298,968.72
9/30/2020	Buy	15,000	$2.97	$44,550.00	4,787,693
10/3/2019	Buy	10,000	$4.89	$48,900.00	4,772,693
6/11/2019	Buy	25,000	$3.23	$80,750.00	4,762,693
12/19/2018	Buy	20,000	$2.24	$44,800.00	4,737,693
4/3/2018	Buy	20,000	$2.29	$45,800.00
9/5/2017	Buy	20,000	$2.58	$51,600.00	4,471,026
6/14/2016	Buy	105,300	$0.65	$68,445.00	4,393,109
4/26/2016	Buy	50,000	$0.65	$32,500.00	4,287,809
12/28/2015	Buy	25,000	$2.39	$59,750.00	4,237,809
10/1/2015	Buy	10,000	$2.81	$28,100.00	4,137,262
4/27/2015	Buy	5,000	$3.79	$18,950.00
1/8/2015	Buy	50,000	$2.80	$140,000.00
10/21/2013	Buy	50,000	$1.59	$79,500.00
2/19/2013	Buy	50,000	$0.46	$23,000.00
12/17/2012	Buy	100,000	$0.45	$45,000.00
11/15/2012	Buy	100,000	$0.42	$42,000.00

Patrick J. McEnany Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.69

$21.53

$22.73

50 Day Range

MA: $20.97

$19.37

$23.93

2 Week Range

Now: $21.69

$13.00

$24.27

Volume

1,226,194 shs

Average Volume

1,194,411 shs

Market Capitalization

$2.59 billion

P/E Ratio

18.38

Dividend Yield

N/A

Beta

0.75

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>